CancerWorld shared a post on LinkedIn:
“Empowering Patients in Europe’s New HTA Framework.
Cancer patients across the EU often face long delays, even after European Medicines Agency (EMA) approval, before accessing new treatments.
The EU’s new Health Technology Assessment (HTA) Regulation, effective January 2025, aims to change that by introducing a unified evaluation process.
Key highlights:
- Joint Clinical Assessments (JCAs): Streamlining clinical evaluations at the EU level.
- Patient Involvement: Ensuring patient perspectives are integrated throughout the assessment process.
While challenges remain, this shift marks a significant step towards faster and more equitable access to life-saving therapies.
Read the full article.”
More posts featuring CancerWorld.